Yarchoan M - Search Results

1

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Leaf RK, et al. Among authors: yarchoan m. Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13. Am J Hematol. 2019. PMID: 30790338 Free PMC article. Clinical Trial.

2

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA. Diehl A, et al. Among authors: yarchoan m. Oncotarget. 2017 Dec 14;8(69):114268-114280. doi: 10.18632/oncotarget.23217. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371985 Free PMC article.

3

Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis.

Osipov A, Lim SJ, Popovic A, Azad NS, Laheru DA, Zheng L, Jaffee EM, Wang H, Yarchoan M. Osipov A, et al. Among authors: yarchoan m. Clin Cancer Res. 2020 Sep 15;26(18):4842-4851. doi: 10.1158/1078-0432.CCR-20-0458. Epub 2020 Jun 25. Clin Cancer Res. 2020. PMID: 32586938 Free PMC article.

4

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.

Chen KY, Popovic A, Hsiehchen D, Baretti M, Griffith P, Bista R, Baghdadi A, Kamel IR, Simon SM, Migler RD, Yarchoan M. Chen KY, et al. Among authors: yarchoan m. Cancers (Basel). 2022 Oct 30;14(21):5347. doi: 10.3390/cancers14215347. Cancers (Basel). 2022. PMID: 36358766 Free PMC article.

5

Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.

Kim AK, Gani F, Layman AJ, Besharati S, Zhu Q, Succaria F, Engle EL, Bhaijee F, Goggins MB, Llosa NJ, Pawlik TM, Yarchoan M, Jaffee EM, Simons HC, Taube JM, Anders RA. Kim AK, et al. Among authors: yarchoan m. Cancer Immunol Res. 2019 May;7(5):805-812. doi: 10.1158/2326-6066.CIR-18-0499. Epub 2019 Mar 22. Cancer Immunol Res. 2019. PMID: 30902819 Free PMC article.

6

Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.

Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J. Balaji A, et al. Among authors: yarchoan m. J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. Epub 2019 Aug 6. J Oncol Pract. 2019. PMID: 31386608 Free PMC article.

7

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.

Ho WJ, Danilova L, Lim SJ, Verma R, Xavier S, Leatherman JM, Sztein MB, Fertig EJ, Wang H, Jaffee E, Yarchoan M. Ho WJ, et al. Among authors: yarchoan m. J Immunother Cancer. 2020 Apr;8(1):e000394. doi: 10.1136/jitc-2019-000394. J Immunother Cancer. 2020. PMID: 32303615 Free PMC article.

8

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM. Hopkins AC, et al. Among authors: yarchoan m. JCI Insight. 2018 Jul 12;3(13):e122092. doi: 10.1172/jci.insight.122092. JCI Insight. 2018. PMID: 29997287 Free PMC article. Clinical Trial.

9

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas.

Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H. Ho WJ, et al. Among authors: yarchoan m. J Immunother Cancer. 2018 Aug 31;6(1):84. doi: 10.1186/s40425-018-0395-x. J Immunother Cancer. 2018. PMID: 30170629 Free PMC article.

10

Weakness and Myalgia in a Patient With Hepatocellular Carcinoma Undergoing Checkpoint Inhibitor Therapy.

Shah PP, Romo CG, Yarchoan M. Shah PP, et al. Among authors: yarchoan m. JAMA Oncol. 2019 Oct 1;5(10):1497-1498. doi: 10.1001/jamaoncol.2019.2304. JAMA Oncol. 2019. PMID: 31465106 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page